For the year ending 2025-12-31, PYXS has $91,520K in assets. $38,112K in debts. $15,422K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 15,422 | |||
| Marketable debt securities | 51,435 | |||
| Restricted cash | 1,472 | |||
| Prepaid expenses and other current assets | 3,776 | |||
| Total current assets | 72,105 | |||
| Property and equipment gross | 15,004 | |||
| Less accumulated depreciation and amortization | 7,007 | |||
| Property and equipment, net | 7,997 | |||
| Intangible assets, net | 0 | |||
| Operating lease right-of-use asset | 11,418 | |||
| Total assets | 91,520 | |||
| Accounts payable | 10,885 | |||
| Accrued expenses and other current liabilities | 8,554 | |||
| Operating lease liabilities, current portion | 1,692 | |||
| Total current liabilities | 21,131 | |||
| Operating lease liabilities, net of current portion | 16,958 | |||
| Financing lease liabilities, net of current portion | 23 | |||
| Total liabilities | 38,112 | |||
| Common stock, par value 0.001 per share 190,000,000 shares authorized 62,690,229 and 59,967,814 shares issued and outstanding as of december 31, 2025 and december 31, 2024, respectively | 63 | |||
| Additional paid-in capital | 496,469 | |||
| Accumulated other comprehensive income | 53 | |||
| Accumulated deficit | -443,177 | |||
| Total stockholders' equity | 53,408 | |||
| Total liabilities and stockholders' equity | 91,520 | |||
Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS)